Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| IMMUNOMEDICS INCIMMU · Entity 145732 | Director | November 20, 2017 | November 21, 2017 |
| Lantheus Holdings, Inc.LNTH · Entity 690 | Director · CEO | March 05, 2025 | March 07, 2025 |
| RVL Pharmaceuticals plcRVLP · Entity 108806 | Director · Chief Executive Officer | August 08, 2022 | August 09, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
IMMUNOMEDICS INC
Report date November 20, 2017 · Filed November 21, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 90,788 |
Ending reported balance
After 2017-11-20 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2017-11-20 · Exercise / conversion · Acquired 15,000 · Balance 99,178 Row 2 · 2017-11-20 · Sale · Disposed 8,390 · Balance 90,788 F1: The price in column 4 is a weighted average price. The prices actually received by the reporting person in this transaction range from $11.88 to $11.92. F2: The reporting person has provided to the issuer, and the issuer will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range reported. |
| Stock Options (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.16 · Expires 2017-12-01 | Direct | 0 |
Reported balance
After 2017-11-20 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2017-11-20 · Exercise / conversion · Disposed 15,000 · Balance 0 |
Filing footnotes · ownership attribution and instrument terms
F1: The price in column 4 is a weighted average price. The prices actually received by the reporting person in this transaction range from $11.88 to $11.92.
F2: The reporting person has provided to the issuer, and the issuer will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range reported.
Lantheus Holdings, Inc.
Report date March 05, 2025 · Filed March 07, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 232,420 |
Reported balance
After 2025-03-05 transaction · row 1
1 source rowRow 1 · 2025-03-05 · Grant · Acquired 70,909 · Balance 232,420 F1: Consists of 23,636 restricted stock units that vest in equal installments over a three-year period and 47,273 Total Shareholder Return performance-based restricted stock units ("PSUs") that cliff vest following a three-year performance period. The amount of PSUs included in this Report reflects the target award; however, the ultimate award size can range from 0% to 200% of the target based on the actual performance achieved at the end of the performance period. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $100.48 · Expires 2035-03-05 | Direct | 41,347 |
Reported balance
After 2025-03-05 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2025-03-05 · Grant · Acquired 41,347 · Balance 41,347 F2: The option vests in three equal annual installments beginning on March 5, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: Consists of 23,636 restricted stock units that vest in equal installments over a three-year period and 47,273 Total Shareholder Return performance-based restricted stock units ("PSUs") that cliff vest following a three-year performance period. The amount of PSUs included in this Report reflects the target award; however, the ultimate award size can range from 0% to 200% of the target based on the actual performance achieved at the end of the performance period.
F2: The option vests in three equal annual installments beginning on March 5, 2026.
RVL Pharmaceuticals plc
Report date August 08, 2022 · Filed August 09, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 2,976,020 |
Reported balance
After 2022-08-08 transaction · row 1
1 source rowRow 1 · 2022-08-08 · Purchase · Acquired 850,000 · Balance 2,976,020 |
Past disclosures · reporting ended (2)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
ALERE INC.
Report date October 03, 2017 · Filed October 03, 2017
Section 16 reporting ended · disclosed 2017-10-03. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2017-10-03 transaction · row 1
1 source rowRow 1 · 2017-10-03 · Disposition to issuer · Disposed 5,530 · Balance 0 F1: Pursuant to that certain Agreement and Plan of Merger, dated as of January 30, 2016, as amended on April 13, 2017 (the "Merger Agreement"), between Alere Inc. (the "Company") and Abbott Laboratories, at the Effective Time (as defined in the Merger Agreement) (the "Effective Time"), each of these shares of the Company's common stock (the "Common Stock") was converted into the right to receive $51.00 (the "Merger Consideration"). |
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $33.73 | Direct | 0 |
Reported balance
After 2017-10-03 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2017-10-03 · Disposition to issuer · Disposed 53,756 · Balance 0 F2: Pursuant to the Merger Agreement, at the Effective Time, each outstanding Employee Stock Option, whether vested or unvested, was canceled and converted into the right to receive a lump-sum cash payment equal to the product of (i) the number of shares of Common Stock for which such Employee Stock Option has not been exercised and (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Employee Stock Option. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to that certain Agreement and Plan of Merger, dated as of January 30, 2016, as amended on April 13, 2017 (the "Merger Agreement"), between Alere Inc. (the "Company") and Abbott Laboratories, at the Effective Time (as defined in the Merger Agreement) (the "Effective Time"), each of these shares of the Company's common stock (the "Common Stock") was converted into the right to receive $51.00 (the "Merger Consideration").
F2: Pursuant to the Merger Agreement, at the Effective Time, each outstanding Employee Stock Option, whether vested or unvested, was canceled and converted into the right to receive a lump-sum cash payment equal to the product of (i) the number of shares of Common Stock for which such Employee Stock Option has not been exercised and (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Employee Stock Option.
Organogenesis Holdings Inc.
Report date December 10, 2018 · Filed December 12, 2018
Section 16 reporting ended · disclosed 2018-12-12. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class B Ordinary SharesSEC Table II · derivative / convertible security | Direct | 133,589 |
Reported balance
After 2018-12-10 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2018-12-10 · Disposition to issuer · Disposed 442,151 · Balance 133,589 F1: Pursuant to the Amended and Restated Memorandum and Articles of Association (the "Articles") of Avista Healthcare Public Acquisition Corp. (the "Issuer"), the Class B ordinary shares, par value $0.0001 per share (the "Class B Shares") will automatically convert into Class A ordinary shares, par value $0.0001 per share, of the Issuer at the time of the Issuer's Business Combination, as defined in the Articles, on a one-for-one basis, subject to adjustment, and have no expiration date. F2: 442,151 Class B ordinary shares were forfeited to the Issuer for no consideration prior to the closing of the Business Combination. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the Amended and Restated Memorandum and Articles of Association (the "Articles") of Avista Healthcare Public Acquisition Corp. (the "Issuer"), the Class B ordinary shares, par value $0.0001 per share (the "Class B Shares") will automatically convert into Class A ordinary shares, par value $0.0001 per share, of the Issuer at the time of the Issuer's Business Combination, as defined in the Articles, on a one-for-one basis, subject to adjustment, and have no expiration date.
F2: 442,151 Class B ordinary shares were forfeited to the Issuer for no consideration prior to the closing of the Business Combination.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 05, 2025 Filed Mar 7, 2025 17:43 UTC | Lantheus Holdings, Inc. LNTH · Entity 690 | GrantStock Option (right to buy) · Derivative | 41,347 | $0.00 Strike: $100.48 | $0.00 |
DisclosureSEC source: 0001062993-25-004984 · form4.xml · derivative · entry 2 MARKISON BRIAN A · CIK 0001283061 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 41,347 Underlying: Common Stock · 41,347 shares Expires 2035-03-05 F2 · derivative.exercise_date: The option vests in three equal annual installments beginning on March 5, 2026. Read SEC document |
| March 05, 2025 Filed Mar 7, 2025 17:43 UTC | Lantheus Holdings, Inc. LNTH · Entity 690 | GrantCommon Stock | 70,909 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-25-004984 · form4.xml · nonDerivative · entry 1 MARKISON BRIAN A · CIK 0001283061 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 232,420 F1 · kind: Consists of 23,636 restricted stock units that vest in equal installments over a three-year period and 47,273 Total Shareholder Return performance-based restricted stock units ("PSUs") that cliff vest following a three-year performance period. The amount of PSUs included in this Report reflects the target award; however, the ultimate award size can range from 0% to 200% of the target based on the actual performance achieved at the end of the performance period. Read SEC document |
| March 03, 2025 Filed Mar 5, 2025 17:12 UTC | Lantheus Holdings, Inc. LNTH · Entity 690 | Tax withholdingCommon Stock | 8,637 | $94.86 | $819,305.82 |
DisclosureSEC source: 0001062993-25-004625 · form4.xml · nonDerivative · entry 1 MARKISON BRIAN A · CIK 0001283061 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 161,511 Read SEC document |
| December 19, 2024 Filed Dec 23, 2024 19:33 UTC | Lantheus Holdings, Inc. LNTH · Entity 690 | Exercise / conversionStock Option (right to buy) · Derivative | 16,666 | $0.00 Strike: $6.00 | $0.00 |
DisclosureSEC source: 0001062993-24-021182 · form4.xml · derivative · entry 5 MARKISON BRIAN A · CIK 0001283061 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 16,666 shares Expires 2025-06-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: 100% of the shares subject to the option are fully vested and exercisable. Read SEC document |
| December 19, 2024 Filed Dec 23, 2024 19:33 UTC | Lantheus Holdings, Inc. LNTH · Entity 690 | Exercise / conversionStock Option (right to buy) · Derivative | 16,102 | $0.00 Strike: $12.42 | $0.00 |
DisclosureSEC source: 0001062993-24-021182 · form4.xml · derivative · entry 4 MARKISON BRIAN A · CIK 0001283061 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 16,102 shares Expires 2025-01-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: 100% of the shares subject to the option are fully vested and exercisable. Read SEC document |
| December 19, 2024 Filed Dec 23, 2024 19:33 UTC | Lantheus Holdings, Inc. LNTH · Entity 690 | Tax withholdingCommon Stock | 15,446 | $91.15 | $1,407,902.90 |
DisclosureSEC source: 0001062993-24-021182 · form4.xml · nonDerivative · entry 3 MARKISON BRIAN A · CIK 0001283061 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 170,148 Read SEC document |
| December 19, 2024 Filed Dec 23, 2024 19:33 UTC | Lantheus Holdings, Inc. LNTH · Entity 690 | Exercise / conversionCommon Stock | 16,666 | $6.00 | $99,996.00 |
DisclosureSEC source: 0001062993-24-021182 · form4.xml · nonDerivative · entry 2 MARKISON BRIAN A · CIK 0001283061 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 185,594 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 19, 2024 Filed Dec 23, 2024 19:33 UTC | Lantheus Holdings, Inc. LNTH · Entity 690 | Exercise / conversionCommon Stock | 16,102 | $12.42 | $199,986.84 |
DisclosureSEC source: 0001062993-24-021182 · form4.xml · nonDerivative · entry 1 MARKISON BRIAN A · CIK 0001283061 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 168,928 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 01, 2024 Filed Mar 5, 2024 20:09 UTC | Lantheus Holdings, Inc. LNTH · Entity 690 | GrantCommon Stock | 131,496 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-026632 · ownership.xml · nonDerivative · entry 1 MARKISON BRIAN A · CIK 0001283061 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 152,826 F1 · kind: Consists of 65,748 restricted stock units that vest in equal installments over a three-year period and 65,748 Total Shareholder Return performance-based restricted stock units ("PSUs") that cliff vest following a three-year performance period. The amount of PSUs included in this Report reflects the target award, however the ultimate award size can range from 0% to 200% of the target based on the actual performance achieved at the end of the performance period. Read SEC document |
| May 11, 2023 Filed May 15, 2023 18:44 UTC | Lantheus Holdings, Inc. LNTH · Entity 690 | GrantStock Option (right to buy) · Derivative | 3,798 | $0.00 Strike: $99.38 | $0.00 |
DisclosureSEC source: 0000899243-23-013002 · doc4.xml · derivative · entry 2 MARKISON BRIAN A · CIK 0001283061 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,798 Underlying: Common Stock · 3,798 shares Expires 2033-05-11 Read SEC document |
| May 11, 2023 Filed May 15, 2023 18:44 UTC | Lantheus Holdings, Inc. LNTH · Entity 690 | GrantCommon Stock | 2,012 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-23-013002 · doc4.xml · nonDerivative · entry 1 MARKISON BRIAN A · CIK 0001283061 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,330 Read SEC document |
| March 27, 2023 Filed Mar 29, 2023 17:51 UTC | Lantheus Holdings, Inc. LNTH · Entity 690 | SaleCommon Stock | 13,290 | $81.13 | $1,078,217.70 |
DisclosureSEC source: 0000950170-23-010673 · ownership.xml · nonDerivative · entry 1 MARKISON BRIAN A · CIK 0001283061 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,318 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 24, 2023. Read SEC document |
| September 08, 2022 Filed Sep 12, 2022 16:30 UTC | Lantheus Holdings, Inc. LNTH · Entity 690 | Exercise / conversionStock Option (right to buy) · Derivative | 11,725 | $0.00 Strike: $17.06 | $0.00 |
DisclosureSEC source: 0000899243-22-030800 · doc4.xml · derivative · entry 9 MARKISON BRIAN A · CIK 0001283061 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 11,725 shares Expires 2024-01-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 4, 2022. F6 · derivative.exercise_date: The stock options under this grant vested in equal monthly installments over the twelve months beginning on January 23, 2014. Read SEC document |
| September 08, 2022 Filed Sep 12, 2022 16:30 UTC | Lantheus Holdings, Inc. LNTH · Entity 690 | Exercise / conversionStock Option (right to buy) · Derivative | 9,464 | $0.00 Strike: $19.11 | $0.00 |
DisclosureSEC source: 0000899243-22-030800 · doc4.xml · derivative · entry 8 MARKISON BRIAN A · CIK 0001283061 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 9,646 shares Expires 2023-05-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 4, 2022. F5 · derivative.exercise_date: The stock options under this grant vested in equal monthly installments over the twelve months beginning on May 6, 2013. Read SEC document |
| September 08, 2022 Filed Sep 12, 2022 16:30 UTC | Lantheus Holdings, Inc. LNTH · Entity 690 | Exercise / conversionStock Option (right to buy) · Derivative | 3,263 | $0.00 Strike: $21.13 | $0.00 |
DisclosureSEC source: 0000899243-22-030800 · doc4.xml · derivative · entry 7 MARKISON BRIAN A · CIK 0001283061 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,263 shares Expires 2023-04-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 4, 2022. Read SEC document |
| September 08, 2022 Filed Sep 12, 2022 16:30 UTC | Lantheus Holdings, Inc. LNTH · Entity 690 | SaleCommon Stock | 13,788 | $84.84 | $1,169,784.95 |
DisclosureSEC source: 0000899243-22-030800 · doc4.xml · nonDerivative · entry 6 MARKISON BRIAN A · CIK 0001283061 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,608 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 4, 2022. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $84.48 to $85.33, inclusive. The reporting person undertakes to provide to LNTH, any security holder of LNTH or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (4) to this Form 4. Read SEC document |
| September 08, 2022 Filed Sep 12, 2022 16:30 UTC | Lantheus Holdings, Inc. LNTH · Entity 690 | SaleCommon Stock | 23,852 | $84.10 | $2,006,043.84 |
DisclosureSEC source: 0000899243-22-030800 · doc4.xml · nonDerivative · entry 5 MARKISON BRIAN A · CIK 0001283061 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,396 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 4, 2022. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $83.48 to $84.475, inclusive. The reporting person undertakes to provide to LNTH, any security holder of LNTH or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (3) to this Form 4. Read SEC document |
| September 08, 2022 Filed Sep 12, 2022 16:30 UTC | Lantheus Holdings, Inc. LNTH · Entity 690 | SaleCommon Stock | 4,172 | $83.05 | $346,463.74 |
DisclosureSEC source: 0000899243-22-030800 · doc4.xml · nonDerivative · entry 4 MARKISON BRIAN A · CIK 0001283061 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,248 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 4, 2022. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $82.455 to $83.44, inclusive. The reporting person undertakes to provide to Lantheus Holdings, Inc., ("LNTH") any security holder of LNTH or the staff of the Securities and Exchange Commission ("SEC"), upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2) to this Form 4. Read SEC document |
| September 08, 2022 Filed Sep 12, 2022 16:30 UTC | Lantheus Holdings, Inc. LNTH · Entity 690 | Exercise / conversionCommon Stock | 11,725 | $17.06 | $200,028.50 |
DisclosureSEC source: 0000899243-22-030800 · doc4.xml · nonDerivative · entry 3 MARKISON BRIAN A · CIK 0001283061 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 74,420 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 4, 2022. Read SEC document |
| September 08, 2022 Filed Sep 12, 2022 16:30 UTC | Lantheus Holdings, Inc. LNTH · Entity 690 | Exercise / conversionCommon Stock | 9,464 | $19.11 | $180,857.04 |
DisclosureSEC source: 0000899243-22-030800 · doc4.xml · nonDerivative · entry 2 MARKISON BRIAN A · CIK 0001283061 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,695 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 4, 2022. Read SEC document |
| September 08, 2022 Filed Sep 12, 2022 16:30 UTC | Lantheus Holdings, Inc. LNTH · Entity 690 | Exercise / conversionCommon Stock | 3,263 | $21.13 | $68,947.19 |
DisclosureSEC source: 0000899243-22-030800 · doc4.xml · nonDerivative · entry 1 MARKISON BRIAN A · CIK 0001283061 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,231 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 4, 2022. Read SEC document |
| September 06, 2022 Filed Sep 8, 2022 16:30 UTC | Lantheus Holdings, Inc. LNTH · Entity 690 | Exercise / conversionStock Option (right to buy) · Derivative | 1,693 | $0.00 Strike: $19.78 | $0.00 |
DisclosureSEC source: 0000899243-22-030670 · doc4.xml · derivative · entry 3 MARKISON BRIAN A · CIK 0001283061 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,693 shares Expires 2022-09-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 4, 2022. Read SEC document |
| September 06, 2022 Filed Sep 8, 2022 16:30 UTC | Lantheus Holdings, Inc. LNTH · Entity 690 | SaleCommon Stock | 1,693 | $78.50 | $132,900.50 |
DisclosureSEC source: 0000899243-22-030670 · doc4.xml · nonDerivative · entry 2 MARKISON BRIAN A · CIK 0001283061 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,968 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 4, 2022. Read SEC document |
| September 06, 2022 Filed Sep 8, 2022 16:30 UTC | Lantheus Holdings, Inc. LNTH · Entity 690 | Exercise / conversionCommon Stock | 1,693 | $19.78 | $33,487.54 |
DisclosureSEC source: 0000899243-22-030670 · doc4.xml · nonDerivative · entry 1 MARKISON BRIAN A · CIK 0001283061 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,661 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 4, 2022. Read SEC document |
| August 08, 2022 Filed Aug 9, 2022 17:22 UTC | RVL Pharmaceuticals plc RVLP · Entity 108806 | PurchaseOrdinary Shares | 850,000 | $1.55 | $1,317,500.00 |
DisclosureSEC source: 0001104659-22-088034 · tm2222999-4_4seq1.xml · nonDerivative · entry 1 MARKISON BRIAN A · CIK 0001283061 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,976,020 Read SEC document |
| May 06, 2022 Filed May 10, 2022 16:40 UTC | Lantheus Holdings, Inc. LNTH · Entity 690 | GrantStock Option (right to buy) · Derivative | 3,616 | $0.00 Strike: $64.20 | $0.00 |
DisclosureSEC source: 0000899243-22-017452 · doc4.xml · derivative · entry 2 MARKISON BRIAN A · CIK 0001283061 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,616 Underlying: Common Stock · 3,616 shares Expires 2032-05-06 Read SEC document |
| May 06, 2022 Filed May 10, 2022 16:40 UTC | Lantheus Holdings, Inc. LNTH · Entity 690 | GrantCommon Stock | 2,180 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-22-017452 · doc4.xml · nonDerivative · entry 1 MARKISON BRIAN A · CIK 0001283061 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,968 F1 · shares: The restricted stock units cliff vest on May 6, 2023. Read SEC document |
| May 06, 2022 Filed May 12, 2022 17:48 UTC Amendment | Lantheus Holdings, Inc. LNTH · Entity 690 | GrantStock Option (right to buy) · Derivative | 4,068 | $0.00 Strike: $64.20 | $0.00 |
DisclosureSEC source: 0000899243-22-017799 · doc4a.xml · derivative · entry 1 MARKISON BRIAN A · CIK 0001283061 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,068 Underlying: Common Stock · 4,068 shares Expires 2032-05-06 F1 · shares: The Form 4 originally filed on May 10, 2022 inadvertently reported 3,616 options granted on May 6, 2022 due to an administrative error. The correct amount of options granted on May 6, 2022 is 4,068 and is being reported in this amendment. F1 · derivative.underlying_shares: The Form 4 originally filed on May 10, 2022 inadvertently reported 3,616 options granted on May 6, 2022 due to an administrative error. The correct amount of options granted on May 6, 2022 is 4,068 and is being reported in this amendment. F1 · balance_after: The Form 4 originally filed on May 10, 2022 inadvertently reported 3,616 options granted on May 6, 2022 due to an administrative error. The correct amount of options granted on May 6, 2022 is 4,068 and is being reported in this amendment. Read SEC document |
| November 04, 2021 Filed Nov 8, 2021 16:05 UTC | RVL Pharmaceuticals plc OSMT · Entity 108806 | GrantShare Option (Right to Buy) · Derivative | 615,000 | $0.00 Strike: $1.80 | $0.00 |
DisclosureSEC source: 0001104659-21-135636 · tm2132232-1_4seq1.xml · derivative · entry 1 MARKISON BRIAN A · CIK 0001283061 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 615,000 Underlying: Ordinary Shares · 615,000 shares Expires 2031-11-04 F1 · derivative.exercise_date: The option vests as to 25% of the ordinary shares underlying the award on the first anniversary of the grant and as to the remaining 75% of the shares in thirty-six (36) equal monthly installments thereafter. Read SEC document |
| May 10, 2021 Filed May 12, 2021 16:30 UTC | Lantheus Holdings, Inc. LNTH · Entity 690 | GrantCommon Stock | 8,513 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-019266 · doc4.xml · nonDerivative · entry 1 MARKISON BRIAN A · CIK 0001283061 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,788 Read SEC document |
| October 01, 2020 Filed Oct 5, 2020 16:52 UTC | Lantheus Holdings, Inc. LNTH · Entity 690 | GrantCommon Stock | 2,277 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-027279 · doc4.xml · nonDerivative · entry 1 MARKISON BRIAN A · CIK 0001283061 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,275 F1 · kind: As previously disclosed, the Board of Directors of the Company elected to receive all remaining compensation payable in 2020 in the form of time-based restricted stock units, rather than in cash. The transaction reported in this Form 4 reports the additional restricted stock units earned by the reporting person for the compensation payable in the fourth quarter of 2020, as calculated by the Company on October 1, 2020. Read SEC document |
| August 10, 2020 Filed Aug 12, 2020 17:37 UTC | Lantheus Holdings, Inc. LNTH · Entity 690 | GrantCommon Stock | 1,354 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-022151 · doc4.xml · nonDerivative · entry 1 MARKISON BRIAN A · CIK 0001283061 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,998 F1 · kind: As previously disclosed, including most recently in our Form 10-Q for the fiscal period ended June 30, 2020, the Board of Directors of the Company elected to receive all remaining compensation payable in 2020 in the form of time-based restricted stock units, rather than in cash. The transaction reported in this Form 4 reports the additional restricted stock units earned by the reporting person for the compensation payable in the third quarter of 2020, as finally calculated by the Company on August 10, 2020. Read SEC document |
| May 20, 2020 Filed May 22, 2020 16:26 UTC | RVL Pharmaceuticals plc OSMT · Entity 108806 | GrantPerformance-Based Restricted Stock Units · Derivative | 249,787 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-20-065388 · a4.xml · derivative · entry 2 MARKISON BRIAN A · CIK 0001283061 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 249,787 Underlying: Ordinary Shares · 249,787 shares Expires not disclosed F2 · derivative.exercise_price: The performance-based restricted stock units represent a contingent right to receive, upon vesting, a varying number of the registrant's ordinary shares based on certain pre-determined thresholds for the closing price of registrant's ordinary shares on the Nasdaq Global Select Market. The performance-based restricted stock units vest on the fifth anniversary of the date of grant and, upon vesting, will convert into 0%, 50%, 100% or 150% of the target number of ordinary shares listed in Column 7 of Table II, subject to the individual limits set forth in the incentive plan under which the performance-based restricted stock units were granted. F2 · derivative.exercise_date: The performance-based restricted stock units represent a contingent right to receive, upon vesting, a varying number of the registrant's ordinary shares based on certain pre-determined thresholds for the closing price of registrant's ordinary shares on the Nasdaq Global Select Market. The performance-based restricted stock units vest on the fifth anniversary of the date of grant and, upon vesting, will convert into 0%, 50%, 100% or 150% of the target number of ordinary shares listed in Column 7 of Table II, subject to the individual limits set forth in the incentive plan under which the performance-based restricted stock units were granted. F2 · derivative.expiration_date: The performance-based restricted stock units represent a contingent right to receive, upon vesting, a varying number of the registrant's ordinary shares based on certain pre-determined thresholds for the closing price of registrant's ordinary shares on the Nasdaq Global Select Market. The performance-based restricted stock units vest on the fifth anniversary of the date of grant and, upon vesting, will convert into 0%, 50%, 100% or 150% of the target number of ordinary shares listed in Column 7 of Table II, subject to the individual limits set forth in the incentive plan under which the performance-based restricted stock units were granted. F2 · derivative.underlying_shares: The performance-based restricted stock units represent a contingent right to receive, upon vesting, a varying number of the registrant's ordinary shares based on certain pre-determined thresholds for the closing price of registrant's ordinary shares on the Nasdaq Global Select Market. The performance-based restricted stock units vest on the fifth anniversary of the date of grant and, upon vesting, will convert into 0%, 50%, 100% or 150% of the target number of ordinary shares listed in Column 7 of Table II, subject to the individual limits set forth in the incentive plan under which the performance-based restricted stock units were granted. Read SEC document |
| May 20, 2020 Filed May 22, 2020 16:26 UTC | RVL Pharmaceuticals plc OSMT · Entity 108806 | GrantOrdinary Shares | 249,787 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-20-065388 · a4.xml · nonDerivative · entry 1 MARKISON BRIAN A · CIK 0001283061 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,126,020 F1 · kind: Represents a grant of restricted stock units. F1 · shares: Represents a grant of restricted stock units. Read SEC document |
| March 03, 2020 Filed Mar 5, 2020 16:31 UTC | Lantheus Holdings, Inc. LNTH · Entity 690 | GrantCommon Stock | 8,095 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-007197 · doc4.xml · nonDerivative · entry 1 MARKISON BRIAN A · CIK 0001283061 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,644 Read SEC document |
| July 10, 2019 Filed Jul 12, 2019 16:05 UTC | Lantheus Holdings, Inc. LNTH · Entity 690 | SaleCommon Stock | 4,918 | $28.07 | $138,048.26 |
DisclosureSEC source: 0000899243-19-019527 · doc4.xml · nonDerivative · entry 1 MARKISON BRIAN A · CIK 0001283061 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,549 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 15, 2019. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.07 to $28.15, inclusive. The reporting person undertakes to provide to Lantheus Holdings, Inc. ("LNTH"), any security holder of LNTH or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2) to this Form 4. Read SEC document |
| July 03, 2019 Filed Jul 5, 2019 16:05 UTC | Lantheus Holdings, Inc. LNTH · Entity 690 | SaleCommon Stock | 5,000 | $28.41 | $142,050.00 |
DisclosureSEC source: 0000899243-19-019244 · doc4.xml · nonDerivative · entry 1 MARKISON BRIAN A · CIK 0001283061 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,467 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 15, 2019. Read SEC document |
| June 26, 2019 Filed Jun 28, 2019 16:30 UTC | Lantheus Holdings, Inc. LNTH · Entity 690 | SaleCommon Stock | 5,000 | $27.67 | $138,361.00 |
DisclosureSEC source: 0000899243-19-018534 · doc4.xml · nonDerivative · entry 1 MARKISON BRIAN A · CIK 0001283061 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,467 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 15, 2019. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.62 to $27.81, inclusive. The reporting person undertakes to provide to Lantheus Holdings, Inc., ("LNTH") any security holder of LNTH or the staff of the Securities and Exchange Commission ("SEC"), upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2) to this Form 4. Read SEC document |
| June 19, 2019 Filed Jun 21, 2019 16:30 UTC | Lantheus Holdings, Inc. LNTH · Entity 690 | SaleCommon Stock | 5,000 | $27.40 | $137,014.50 |
DisclosureSEC source: 0000899243-19-017814 · doc4.xml · nonDerivative · entry 1 MARKISON BRIAN A · CIK 0001283061 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,467 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 15, 2019. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.40 to $27.43, inclusive. The reporting person undertakes to provide to Lantheus Holdings, Inc., ("LNTH") any security holder of LNTH or the staff of the Securities and Exchange Commission ("SEC"), upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2) to this Form 4. Read SEC document |
| June 12, 2019 Filed Jun 14, 2019 16:30 UTC | Lantheus Holdings, Inc. LNTH · Entity 690 | SaleCommon Stock | 5,000 | $25.27 | $126,365.00 |
DisclosureSEC source: 0000899243-19-017062 · doc4.xml · nonDerivative · entry 1 MARKISON BRIAN A · CIK 0001283061 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,467 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 15, 2019. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.18 to $25.30, inclusive. The reporting person undertakes to provide to Lantheus Holdings, Inc., ("LNTH") any security holder of LNTH or the staff of the Securities and Exchange Commission ("SEC"), upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2) to this Form 4. Read SEC document |
| June 05, 2019 Filed Jun 7, 2019 16:30 UTC | Lantheus Holdings, Inc. LNTH · Entity 690 | SaleCommon Stock | 5,000 | $24.60 | $123,009.50 |
DisclosureSEC source: 0000899243-19-016021 · doc4.xml · nonDerivative · entry 1 MARKISON BRIAN A · CIK 0001283061 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,467 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 15, 2019. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.43 to $24.825, inclusive. The reporting person undertakes to provide to Lantheus Holdings, Inc., ("LNTH") any security holder of LNTH or the staff of the Securities and Exchange Commission ("SEC"), upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2) to this Form 4. Read SEC document |
| May 29, 2019 Filed May 31, 2019 16:30 UTC | Lantheus Holdings, Inc. LNTH · Entity 690 | SaleCommon Stock | 5,000 | $24.29 | $121,453.50 |
DisclosureSEC source: 0000899243-19-015291 · doc4.xml · nonDerivative · entry 1 MARKISON BRIAN A · CIK 0001283061 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,467 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 15, 2019. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.25 to $24.41, inclusive. The reporting person undertakes to provide to Lantheus Holdings, Inc., ("LNTH") any security holder of LNTH or the staff of the Securities and Exchange Commission ("SEC"), upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2) to this Form 4. Read SEC document |
| May 22, 2019 Filed May 24, 2019 16:30 UTC | Lantheus Holdings, Inc. LNTH · Entity 690 | SaleCommon Stock | 5,000 | $24.73 | $123,627.50 |
DisclosureSEC source: 0000899243-19-014739 · doc4.xml · nonDerivative · entry 1 MARKISON BRIAN A · CIK 0001283061 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,467 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 15, 2019. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.65 to $24.785, inclusive. The reporting person undertakes to provide to Lantheus Holdings, Inc., ("LNTH") any security holder of LNTH or the staff of the Securities and Exchange Commission ("SEC"), upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2) to this Form 4. Read SEC document |
| May 15, 2019 Filed May 17, 2019 16:31 UTC | Lantheus Holdings, Inc. LNTH · Entity 690 | SaleCommon Stock | 5,000 | $24.75 | $123,754.50 |
DisclosureSEC source: 0000899243-19-014003 · doc4.xml · nonDerivative · entry 1 MARKISON BRIAN A · CIK 0001283061 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,467 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 15, 2019. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.75 to $24.765, inclusive. The reporting person undertakes to provide to Lantheus Holdings, Inc., ("LNTH") any security holder of LNTH or the staff of the Securities and Exchange Commission ("SEC"), upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2) to this Form 4. Read SEC document |
| May 08, 2019 Filed May 10, 2019 16:31 UTC | Lantheus Holdings, Inc. LNTH · Entity 690 | SaleCommon Stock | 5,000 | $25.22 | $126,115.50 |
DisclosureSEC source: 0000899243-19-013046 · doc4.xml · nonDerivative · entry 1 MARKISON BRIAN A · CIK 0001283061 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,467 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 15, 2019. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.20 to $25.27, inclusive. The reporting person undertakes to provide to Lantheus Holdings, Inc., ("LNTH") any security holder of LNTH or the staff of the Securities and Exchange Commission ("SEC"), upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2) to this Form 4. Read SEC document |
| May 01, 2019 Filed May 2, 2019 16:30 UTC | Lantheus Holdings, Inc. LNTH · Entity 690 | SaleCommon Stock | 5,000 | $23.91 | $119,537.00 |
DisclosureSEC source: 0000899243-19-011782 · doc4.xml · nonDerivative · entry 2 MARKISON BRIAN A · CIK 0001283061 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 77,467 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 15, 2019. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $23.815 to $24.13, inclusive. The reporting person undertakes to provide to Lantheus Holdings, Inc., ("LNTH") any security holder of LNTH or the staff of the Securities and Exchange Commission ("SEC"), upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (3) to this Form 4. Read SEC document |
| April 30, 2019 Filed May 2, 2019 16:30 UTC | Lantheus Holdings, Inc. LNTH · Entity 690 | SaleCommon Stock | 5,000 | $24.30 | $121,519.00 |
DisclosureSEC source: 0000899243-19-011782 · doc4.xml · nonDerivative · entry 1 MARKISON BRIAN A · CIK 0001283061 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 82,467 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 15, 2019. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.25 to $24.35, inclusive. The reporting person undertakes to provide to Lantheus Holdings, Inc., ("LNTH") any security holder of LNTH or the staff of the Securities and Exchange Commission ("SEC"), upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2) to this Form 4. Read SEC document |
| April 23, 2019 Filed Apr 25, 2019 16:30 UTC | Lantheus Holdings, Inc. LNTH · Entity 690 | SaleCommon Stock | 5,000 | $24.07 | $120,368.00 |
DisclosureSEC source: 0000899243-19-011133 · doc4.xml · nonDerivative · entry 1 MARKISON BRIAN A · CIK 0001283061 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,467 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 15, 2019. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.00 to $24.11, inclusive. The reporting person undertakes to provide to Lantheus Holdings, Inc., ("LNTH") any security holder of LNTH or the staff of the Securities and Exchange Commission ("SEC"), upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2) to this Form 4. Read SEC document |
| April 16, 2019 Filed Apr 18, 2019 16:30 UTC | Lantheus Holdings, Inc. LNTH · Entity 690 | SaleCommon Stock | 5,000 | $25.26 | $126,297.50 |
DisclosureSEC source: 0000899243-19-010897 · doc4.xml · nonDerivative · entry 1 MARKISON BRIAN A · CIK 0001283061 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 92,467 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 15, 2019. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.25 to $25.40, inclusive. The reporting person undertakes to provide to Lantheus Holdings, Inc., ("LNTH") any security holder of LNTH or the staff of the Securities and Exchange Commission ("SEC"), upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2) to this Form 4. Read SEC document |
| February 26, 2019 Filed Feb 28, 2019 16:15 UTC | Lantheus Holdings, Inc. LNTH · Entity 690 | GrantCommon Stock | 5,353 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-19-005207 · doc4.xml · nonDerivative · entry 1 MARKISON BRIAN A · CIK 0001283061 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 97,467 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.